Gut microbiota in patients with obesity and metabolic disorders — a systematic review

Zhilu XU1,2,3†, Wei JIANG1†, Wenli HUANG1,2,3, Yu LIN1,2,3, Francis KL. CHAN1,2,3 and Siew C. NG1,2,3*

Abstract

Background: Previous observational studies have demonstrated inconsistent and inconclusive results of changes in the intestinal microbiota in patients with obesity and metabolic disorders. We performed a systematic review to explore evidence for this association across different geography and populations.

Methods: We performed a systematic search of MEDLINE (OvidSP) and Embase (OvidSP) of articles published from Sept 1, 2010, to July 10, 2021, for case–control studies comparing intestinal microbiome of individuals with obesity and metabolic disorders with the microbiome of non-obese, metabolically healthy individuals (controls). The primary outcome was bacterial taxonomic changes in patients with obesity and metabolic disorders as compared to controls. Taxa were defined as “lean-associated” if they were depleted in patients with obesity and metabolic disorders or negatively associated with abnormal metabolic parameters. Taxa were defined as “obesity-associated” if they were enriched in patients with obesity and metabolic disorders or positively associated with abnormal metabolic parameters.

Results: Among 2390 reports screened, we identified 110 full-text articles and 60 studies were included. Proteobacteria was the most consistently reported obesity-associated phylum. Thirteen, nine, and ten studies, respectively, reported Faecalibacterium, Akkermansia, and Alistipes as lean-associated genera. Prevotella and Ruminococcus were obesity-associated genera in studies from the West but lean-associated in the East. Roseburia and Bifidobacterium were lean-associated genera only in the East, whereas Lactobacillus was an obesity-associated genus in the West.

Conclusions: We identified specific bacteria associated with obesity and metabolic disorders in western and eastern populations. Mechanistic studies are required to determine whether these microbes are a cause or product of obesity and metabolic disorders.

Keywords: Obesity, Metabolic disorder, Microbiota

Introduction

Obesity-related metabolic disorders, including type 2 diabetes (T2DM), cardiovascular diseases, and non-alcoholic fatty liver disease (NAFLD), affect 13% of the population and result in 2.8 million deaths each year [1, 2], and are a significant socioeconomic burden to society. Pathophysiology of obesity and metabolic disorders is multi-factorial, and currently, therapies are limited. The role of intestinal microbiota in patients with obesity and metabolic disorders have been extensively studied in the past decade. Humanized mouse models showed that the microbiome in obese subjects appeared to be more efficient in harvesting energy from the diet and may thereby contribute to the pathogenesis of obesity [3, 4]. However, observational studies reported inconsistent and inconclusive changes of intestinal microbiota in patients
with obesity and metabolic disorders [5]. For instance, the Firmicutes and Bacteriodetes ratio (F/B ratio) is not a reproducible marker across human cohorts [6].

Microbial-based therapies such as probiotics aiming to reshape the gut microbial ecosystem have been increasingly explored in the treatment of obesity-related metabolic disorders [7, 8]. Traditional probiotics, primarily consisting of Lactobacillus and Bifidobacterium have been shown to elicit weight loss in subjects with obesity yet the effect sizes were small with large variations of efficacy among different studies [9]. Emerging evidence showed that Akkermansia muciniphila was depleted in patients with obesity-related metabolic disorders. These results have led to mechanistic studies and clinical trials to test its efficacy in the management of obesity and metabolic disorders [10].

Age, geography, and dietary patterns largely affect the gut microbiome [11–13]. The gut microbiota of vegetarians was dominated by Clostridium species [14] whereas subjects who mainly consumed fish and meat had high level of F. prausnitzii [15]. In recent years, the prevalence of childhood obesity has increased sharply. However, only limited data has issued the function and structure of gut microbiota in children and adolescents with obesity [16].

We have therefore conducted a systematic review of case–control studies evaluating the microbiota in patients with obesity and metabolic disorders compared to lean, healthy controls to summarize the current evidence in the relationship between individual members of the microbiota and obesity. We aimed to identify novel candidates as live biotherapeutics to facilitate the treatment of obesity and metabolic disorders.

Materials and methods

Search strategy

This systematic review was performed in accordance with the PRISMA 2009 guidelines [17]. We performed a systematic search of MEDLINE (OvidSP) and Embase (OvidSP) of articles published from Sept 1, 2010 to July 10, 2021 to identify case-control studies comparing gut microbiota in patients with obesity and metabolic disorder and non-obese, metabolically healthy controls. Search strategy is shown in the Appendix.

Study selection and patient population

Studies were included if they were (1) case–control studies comparing gut microbiota in patients with obesity and metabolic disorders and non-obese, metabolically healthy individuals (controls); (2) intestinal microbiota was assessed by next-generation sequencing (NGS; 16s rRNA amplicon or shotgun metagenomic sequencing); and (3) obesity was defined based on body mass index (BMI) ≥ 30kg/m² and metabolic disorders including type 2 diabetes mellitus, non-alcoholic fatty liver disease, cardiovascular disease, and metabolic syndrome were diagnosed according to respective guidelines (Table 1). Studies from all age groups were included. Studies were excluded if they were (1) case reports, reviews, meta-analyses, re-analysis of public datasets, or conference abstracts, (2) without data for individual bacterial groups, (3) not in English, and (4) not a case–control design. Studies of genetic-associated obesity such as Prader–Willi syndrome were also excluded.

Study outcomes

The primary outcome was the bacterial taxonomic changes in patients with obesity and metabolic disorders compared to non-obese, metabolically healthy controls. Secondary outcomes included the changes in bacteria diversity and F/B ratio, subgroup analysis of microbiota changes in adults and children with obesity and metabolic disorders, and in Eastern and Western populations. Data on microbiota community composition were extracted from each study. Taxa were defined as “lean-associated” if they were depleted in patients with obesity and metabolic disorders or negatively associated with abnormal metabolic parameters such as high body mass index (BMI), elevated fasting plasma glucose and elevated serum cholesterol. Taxa were defined as “obesity-associated” if they were enriched in patients with obesity and metabolic disorders or positively associated with abnormal metabolic parameters. Taxon at each level (phylum, class, order, family, genus) was only counted once for each study (i.e., if a genus was both depleted in obesity and negatively associate with fat mass in the same study, it was only counted once).

Eligibility assessment and data extraction

Two authors (JW, HW) independently reviewed studies and excluded based on titles, abstracts, or both to lessen the selection bias and then reviewed selected studies with full text for complete analysis. JW extracted data from studies and entered it into a designated spreadsheet. HW checked the accuracy of this process. The data were re-checked when there was a discrepancy. XZ arbitrated if the discrepancy cannot be resolved by consensus and discussion. The data collected included the following: participant characteristics, including age group, country, types of metabolic disorders, number of patients; types of specimens, microbiota assessment method, microbiome diversity, and Firmicutes/Bacteroides ratio.

Quality assessment

The Newcastle-Ottawa Scale was applied to assess the quality of included studies. The Newcastle-Ottawa Scale
| First author, year | Country | Ethnicity | Disease | Sample size (case) | Sample size (control) | Age (years) | Sample Sequencing Method | Definition of obesity | Definition of metabolic diseases |
|-------------------|---------|-----------|---------|-------------------|----------------------|-------------|-------------------------|---------------------|---------------------------|
| Andoh, 2016 [18] | Japan   | Asian     | OB      | 10                | 10                   | 31–58       | Stool 16s rRNA (V3–V4) | BMI ≥ 35.7 kg/m²   | NA                        |
| Bai, 2019 [19]   | USA     | Caucasian | OB      | 43                | 224                  | 7–18        | Stool 16s rRNA (V4)    | BMI > 95th percentile | NA                        |
| Chen, 2020 [20]  | China   | Asian     | OB      | 28                | 23                   | 6–11        | Stool 16s rRNA (V4)    | NA                  | NA                        |
| Da Silva, 2020 [21]| Trinidad| Asian/Black| OB      | 21                | 30                   | 6–14        | Stool 16s rRNA (not specified) | > 97th percentile | NA                        |
| Gao, 2018 [22]   | China   | Asian     | OB      | 167 (OB: n = 145; OW: n = 22) | 25 | 20 ± 1.6; OW: 20 ± 1.7 | Stool 16s rRNA (V4) | BMI ≥ 30 kg/m² | NA                        |
| Gao, 2018 [23]   | China   | Asian     | OB      | 39                | 38                   | 6.8 ± 1.8; OW: 30 ± 3.7 | Stool 16s rRNA (V3–V4) | BMI ≥ 30 kg/m² | NA                        |
| Haro, 2016 [24]  | Spain   | Caucasian | OB      | 49                | 46                   | Men: 61.15 ± 1.27; Women: 60.31 ± 1.40 | Stool 16s rRNA (V4) | BMI ≥ 30 kg/m² | NA                        |
| Houttu, 2018 [25]| Finland | Caucasian | OB      | 47                | 52                   | 30 ± 5      | Stool 16s rRNA (not specified) | BMI ≥ 30 kg/m² | NA                        |
| Hu, 2015 [26]    | Korea   | Asian     | OB      | 67                | 62                   | 13–16       | Stool 16s rRNA (V1–V3) | BMI ≥ 30 kg/m² or ≥ 99th BMI percentile | NA                        |
| Kaplan, 2019 [27]| USA     | Caucasian | OB      | 294               | 293                  | 18–74       | Stool 16s rRNA (V4)    | BMI ≥ 30 kg/m² | NA                        |
| Liu, 2017 [28]   | China   | Asian     | OB      | 72                | 79                   | OB: 23.6 ± 3.7; NW: 23.2 ± 1.8 | Stool Metagenomics/16s rRNA (V3–V4) | BMI ≥ 30 kg/m² | NA                        |
| Lopez-Contreras, 2018 [29]| Mexico| Hispanic/Latino | OB | 71                | 67                   | 6–12        | Stool 16s rRNA (V4)    | BMI ≥ 30 kg/m² | NA                        |
| Lv, 2019 [30]    | China   | Asian     | OB      | 9                 | 19                   | 18–27       | Stool 16s rRNA (V3–V4) | OW, BMI ≥ 24 kg/m² OB, BMI ≥ 28 kg/m² | NA                        |
| Mendez-Salazar, 2018 [31]| Mexico| Hispanic/Latino | OB | 12                | 12                   | 9–11        | Stool 16s rRNA (V3–V4) | BMI ≥ 30 kg/m² | NA                        |
| Nardelli, 2020 [32]| Italy  | Caucasian | OB      | 19                | 16                   | 20–80       | Duodenal biopsies 16s rRNA V4–V6 | BMI ≥ 30 kg/m² | NA                        |
| Blasco, 2017 [33]| Spain   | Caucasian | OB      | 14                | 13                   | 30–65       | Stool Metagenomics | BMI ≥ 30 kg/m² | NA                        |
| Davis, 2017 [34]| UK      | Caucasian | OB      | 54 (OB/) 27       | 27                   | 19–70       | Stool Metagenomics | NA                  | NA                        |
| First author, year | Country | Ethnicity | Disease | Sample size (case) | Sample size (control) | Age (years) | Sample Sequencing Method | Definition of obesity | Definition of metabolic diseases |
|--------------------|---------|-----------|---------|-------------------|----------------------|-------------|------------------------|---------------------|----------------------------|
| Dominianni, 2015 [35] | USA | Caucasian | OB | OW: n = 27 | 11 | 82 | 30–83 | Stool | 16s rRNA (V4) | BMI ≥ 25 kg/m² | NA |
| Escobar, 2015 [36] | Colombia | Hispanic/ Latino | OB | NA | 30 | 21–60 | Stool | 16s rRNA (V1–V3) | BMI ≥ 30.0 kg/m² | NA |
| Kasai, 2015 [37] | Japan | Asian | OB | 33 | 23 | Non-obese: 45.6 ± 9.6; Obese: 54.4 ± 82 | Stool | 16s rRNA (V3–V4) | BMI ≥ 25 kg/m² | NA |
| Nirmalkar, 2018 [38] | Mexico | Hispanic/ Latino | OB | 96 | 76 | 6–18 | Stool | 16s rRNA V3 | BMI ≥ 95th percentile | NA |
| Otosson, 2018 [39] | Sweden | Caucasian | OB | NA | NA | > 18 | Stool | 16s rRNA (V1–V3) | BMI ≥ 30.0 kg/m² | NA |
| Peters, 2018 [40] | USA | Caucasian | OB | 388 | 211 | 18–86 | Stool | 16s rRNA V4 | BMI ≥ 30 kg/m² | NA |
| Patil, 2012 [41] | India | Asian | OB | 5 | 5 | 21–62 | Stool | 16s rRNA (not specified) | BMI: 25–53 kg/m² | NA |
| Rahat-Rozenbloom, 2014 [42] | Canada | Caucasian | OB | 11 | 11 | > 17 | Stool | 16s rRNA (V6) | BMI ≥ 25 kg/m² | NA |
| Riva, 2017 [43] | Italy | Caucasian | OB | 42 | 36 | 9–16 | Stool | 16s rRNA V3–V4 | BMI z-score | NA |
| Vieira-Silva, 2020 [44] | Belgium | Caucasian | OB | 474 | 414 | 18–76 | Stool | Metagenomics | BMI ≥ 30 kg/m² | NA |
| Ville, 2020 [45] | USA | Hispanic/ Latino | OB | 6 | 39 | 0.5–1 | Stool | 16s rRNA V4 | BMI ≥ 95th percentile | NA |
| Yasar, 2015 [46] | France/ Saudi Arabia | Caucasian/ Asian | OB | 21 | 25 | ≥ 18 | Stool | 16s rRNA (V3–V4) | BMI ≥ 30.0 kg/m² | NA |
| Yun, 2017 [47] | Korea | Asian | OB | 745 (OB: n = 419; OW: n = 326) | 529 | > 18 | Stool | 16s rRNA V3–V4 | BMI ≥ 25 kg/m² | NA |
| Zacarias, 2018 [48] | Finland | Caucasian | OB | 29 (OB: n = 11, OW: n = 18) | 25 | 4.2; OW: 30.4 ± 36; OB: 29.6 ± 2.3 | Stool | 16s rRNA V3–V4 | BMI ≥ 30 kg/m² | NA |
| Allin, 2018 [49] | Denmark | Caucasian | T2DM | 134 | 134 | 55–68 | Stool | 16s rRNA (V4) | NA | Fasting plasma glucose of 6.1–7.0 mmol/l or HbA1c of 42–48 mmol/mol [6.0–6.5%] |
| Barengolts, 2018 [50] | USA | Black | T2DM | 73 | 20 | 35–70 | Stool | 16s rRNA (V3–V4) | NA | HbA1c of 6.5–7.4% |
| First author, year | Country         | Ethnicity | Disease | Sample size (case) | Sample size (control) | Age (years) | Sample | Sequencing Method | Definition of obesity | Definition of metabolic diseases |
|-------------------|----------------|-----------|---------|-------------------|-----------------------|-------------|--------|-------------------|-----------------------|-------------------------|
| Leite, 2017 [51]  | Brazil         | Hispanic/ Latino | T2DM    | 20                | 22                    | 36–75       | Stool  | 16s rRNA (V3–V4) | NA                    | Fasting blood glucose levels ≥ 126 mg/dL |
| Qin, 2012 [52]    | China          | Asian     | T2DM    | 170               | 174                   | 25–86       | Stool  | Metagenomics      | NA                    | Glucose metabolism impairment: fasting hyperglycaemia (fasting venous plasma glucose ≥ 6.1 and < 7.0 mmol/L) or IGT (fasting venous plasma glucose <7 mmol/L, ≥ 7.8 and < 11.1 mg/dL, 2 h after OGTT) or new onset T2DM (fasting glucose ≥ 7 mmol/L, or ≥ 11.1 mmol/L, 2 h after OGTT); Arterial hypertension (AH) (systolic/diastolic blood pressure level of 140/90–159/99 mmHg). |
| Karlsson, 2013 [53] | Sweden        | Caucasian | T2DM    | 102               | 43                    | 70          | Stool  | Metagenomics      | NA                    | NA                      |
| Larsen, 2010 [54] | Denmark        | Caucasian | T2DM    | 18                | 18                    | 31–73       | Stool  | 16s rRNA (V4–V6) | NA                    | The diabetic group had elevated concentration of plasma glucose as determined by OGTT. Non-diabetic group based on the measurements of baseline glucose and biochemical analysis of blood samples. |
| Ahmad, 2019 [55]  | Pakistan       | Asian     | T2DM    | 40                | 20                    | 25–55       | Stool  | 16s rRNA (V3–V4) | NA                    | NA                      |
| Koo, 2019 [56]    | China, Malaysia, and India | Asian | T2DM    | 22                | 13                    | 22–70       | Stool  | 16s rRNA (V3–V6) | waist circumference ≥ 90 cm in men and ≥ 80 cm in women | DM were excluded by the absence of impaired glucose tolerance on fasting blood glucose. |
| Sroka-oleksiak, 2020 [57] | Poland | Caucasian | T2DM    | OB: n = 17; OB+T2DM: n = 22 | 20–70 | Duodenal biopsies | 16s rRNA (V3–V4) | BMI >35 kg/m² | NA |
| Thingholm, 2019 [58] | Germany | Caucasian | T2DM    | OB: n = 494; OB+T2DM: n = 153 | 633 | 21–78 | Stool | Metagenomics/ 16s rRNA (V1–V2) | BMI > 30.0 kg/m² | Fasting glucose level ≥ 125 mg/dL |
| Zhao, 2019 [59]   | China          | Asian     | NAFLD   | OB: n = 18; NAFLD: n = 25 | 15 | 9–17 | Stool | Metagenomics | BMI ≥ 95th percentile | NA |
| Jang, 2015 [60]   | China          | Asian     | NAFLD   | 35                | 30                    | 22–72       | Stool  | 16s rRNA (V3)   | NA                    | Based on evidence of hepatic steatosis via either imaging or histology |
| Shen, 2017 [61]   | Chinese        | Asian     | NAFLD   | 25                | 22                    | > 18        | Stool  | 16s rRNA (V3–V5) | NA                    | NAFLD can be diagnosed by the presence of three findings: (i) the histological findings of liver biopsy are in accord with the pathological diagnostic criteria of fatty liver disease. (ii) there is no history of alcohol drinking habit or the ethanol intake per week was less than 140 g in men (70 g in women) in the past 12 months; (iii) specific diseases that could lead to steatosis, such as viral hepatitis, drug-induced liver disease, |
| First author, year, Country | Ethnicity | Disease | Sample size (case) | Sample size (control) | Age (years) | Sample Sequencing Method | Definition of obesity | Definition of metabolic diseases |
|-----------------------------|-----------|---------|-------------------|-----------------------|-------------|--------------------------|----------------------|---------------------------------|
| Sobhonslidsuk, 2018 [62]    | Thailand  | Asian   | NASH              | 16                    | 8           | Stool 16s rRNA (V3–V4)  | NA                   | total parenteral nutrition, Wilson's disease, and autoimmune liver disease, can be excluded. |
| Wang, 2016 [63]             | China     | Asian   | NAFLD             | 43                    | 83          | Stool 16s rRNA (V3)     | NA                   | Evidence of fatty liver upon ultrasonography |
| Li, 2018 [64]               | China     | Asian   | NAFLD             | 30                    | 37          | Stool 16s rRNA (V4)     | NA                   | The diagnosis of NAFLD was based on the following criteria: (i) abdominal ultrasonography indicated a fatty liver; (ii) the patient's alcohol consumption was less than 20 g/day and 10 g/day for male for female. |
| Nistal, 2019 [65]           | Spain     | Caucasian | NAFLD          | 53                    | 20          | Stool 16s rRNA (V3–V4)  | NA                   | An NAFLD diagnosis was established by clinical, analytical criteria (liver function test) and from ultrasonographic data when steatosis was detected. |
| Yun, 2019 [66]              | Korea     | Asian   | NAFLD             | 76                    | 192         | Stool 16s rRNA (V3–V4)  | BMI ≥ 25 kg/m²       | U/S findings suggestive of fatty liver disease |
| Michail, 2015 [67]          | USA       | Caucasian | NAFLD            | 24                    | 26          | Stool 16s rRNA (not specified) | BMI ≥ 95th percentile | Ultrasound findings and elevated transaminases suggestive of NAFLD |
| Zhu, 2013 [68]              | USA       | Caucasian | NASH              | 47                    | 16          | Stool 16s rRNA (not specified) | BMI ≥ 95th percentile | NAFLD activity score ≥ 5 |
| Chavez-Carbaja, 2019 [69]   | Mexico    | Hispanic/Latino | MS         | 42                    | 25          | Stool 16s rRNA (V4)     | BMI > 95th percentile | At least three of the following issues: waist greater than 102 cm in males or 82 cm in females, triglycerides levels greater or equal to 150 mg/dl; HDL cholesterol levels less than 40 mg/dl in males or less than 50 mg/dl in females, blood pressure greater or equal to 130/85 mmHg and a fasting blood glucose level higher or equal to 100 mg/dl. |
| De La Cuesta-Zuluaga, 2018 [70] | Colombia | Hispanic/Latino | MS         | 291                   | 151         | Stool 16s rRNA (V4)     | BMI ≥ 30.0 kg/m²      | At least two of the following conditions: systolic/diastolic blood pressure >130/85 mm Hg or consumption of antihypertensive medication; fasting triglycerides >150 mg/dl; HDL < 40 mg/dl (men), < 50 mg/dl (women) or consumption of lipid-lowering medication; fasting glucose > 100 mg/dl or consumption of antidiabetic medication; HOMA-IR > 43, and hs-CRP > 43 mg L⁻¹. |
| Gallardo-Becerra, 2020 [71] | Mexico    | Hispanic/Latino | MS         | 17                    | 10          | Stool 16s rRNA (V4)     | BMI > 95th percentile | At least two of the following metabolic traits: (1) triglycerides < 1.1 mmol/L (100 mg/dl); (2) HDL cholesterol < 1.3 mmol/L (50 mg/dl); (3) glucose < 6.1 mmol/L (110 mg/dl); (4) systolic blood pressure > 90th percentile for gender, age, and |
| First author, year | Country | Ethnicity | Disease | Sample size (case) | Sample size (control) | Age (years) | Sample | Sequencing Method | Definition of obesity | Definition of metabolic diseases |
|-------------------|---------|-----------|---------|--------------------|----------------------|-------------|--------|-------------------|----------------------|----------------------------------|
| Gozd-Barszczewska, 2017 [72] | Poland | Caucasian | MS | 15 | 5 | 45–65 | Stool | 16s rRNA (V3–V5) | BMI ≥ 30.0 kg/m² | Lipid profile was assessed based on ESC/EAS Guidelines |
| Kashtanova, 2018 [73] | Russia | Caucasian | MS | 57 | 35 | 25–76 | Stool | 16s rRNA (V3–V4) | BMI ≥ 30 kg/m² and/or waist circumference ≥ 94 cm for men and ≥ 80 cm for women | Glucose metabolism impairment: fasting hyperglycaemia (fasting venous plasma glucose ≥ 6.1 and < 7.0 mmol/L) or IGT (fasting venous plasma glucose < 7 mmol/L ≥ 7.8 and < 11.1 mg/dL 2 h after OGTT) or new onset T2DM (fasting glucose ≥ 7 mmol/L or ≥ 11.1 mmol/L 2 h after OGTT); Arterial hypertension (AH) (systolic/diastolic blood pressure level of 140/90–159/99 mmHg). |
| Lippert, 2017 [74] | Austria | Caucasian | MS | 12 | 8 | 58–71 | Stool | 16s rRNA (V1–V3) | NA | At least two of the following conditions: systolic/diastolic blood pressure ≥ 130/85 mm Hg or consumption of antihypertensive medication; fasting triglycerides ≥ 150 mg/dl; HDL ≤ 40 mg/dl (men), ≤ 50 mg/dl (women), or consumption of lipid-lowering medication; fasting glucose ≥ 100 mg/dl or consumption of antidiabetic medication; HOMA-IR ≥ 4.3, and hs-CRP ≥ 4.3 mg/L. |
| Feinn, 2020 [75] | Italy | Caucasian | NAFLD | 44 | 29 | NAFLD: 133 ± 32; OB without NAFLD: 129 ± 28 | Stool | 16s rRNA (V4) | BMI ≥ 95th percentile | Hepatic fat fraction ≥ 5.5% |
| Li, 2021 [76] | China | Asian | OB | 3 | 3 | OB:34.33 ± 0.47; NW: 25.67 ± 1.25 | Stool | 16s rRNA (V3–V4) | BMI ≥ 30.0 kg/m² | NA |
| Yuan, 2021 [77] | China | Asian | MS | 65 | 21 | 5–15 | Stool | 16s rRNA (V3–V4) | NA | The presence of at least one of the following metabolic traits: (1) Fasting PPG ≥ 5.6 mmol/L; (2) systolic blood pressure ≥ 90th percentile for gender and age; (3) fasting HDL-C < 1.03 mmol/L; and (4) fasting TG ≥ 1.7 mmol/L. |

OW overweight, OB obesity, T2DM diabetes mellitus type 2, NAFLD non-alcoholic fatty liver disease, MS metabolic syndrome, NASH non-alcoholic steatohepatitis, NA not applicable, IGT impaired glucose tolerance

*Refers to a standard developed by the Department of Growth and Development, Capital Institution of Pediatrics, China, to define children of obesity
Results

Study characteristics

Overall, 2390 citations were retrieved; 2280 were excluded based on title, abstract, and the availability of full text; 110 articles were subsequently fully reviewed. After further review, 50 full-text articles were rejected (Fig. 1). The final analysis included 60 studies (Table 1). Of these, 44 studies assessed the gut microbiota in adults and 16 in infants, children, and adolescents. Ethnicity of subjects consisted of Asian, Black, Caucasian, Hispanic, or Latino. Fifty-eight out of 60 (96.7%) studies evaluated intestinal microbiota in stool samples and two studies assessed the microbiota in duodenal biopsies. Thirty-two studies involved patients with obesity [18–48, 76], ten involved patients with T2DM [49–58], eleven involved patients with NAFLD or non-alcoholic steatohepatitis (NASH) [59–68, 75], and seven involved patients with metabolic syndrome [69–74, 77]. General characteristics and diagnostic criteria for obesity and metabolic disorders in each study were summarized in Table 1.

Microbiome assessment methods

Of the 58 studies assessing stool microbiome, 50 studies assessed the gut microbiota by using 16S ribosomal RNA (rRNA) gene sequencing, six used shotgun metagenomic sequencing and two studies applied both 16s rRNA and shotgun metagenomic sequencing. Both studies assessing biopsy microbiome applied 16S rRNA sequencing.

Primary outcomes

At the phylum level, significant changes of phyla Firmicutes, Bacteroidetes, and Proteobacteria were most reported in obese, metabolic diseased subjects compared with controls. Among 60 studies included, 22 studies reported significant changes in Firmicutes with 15 studies showing phylum Firmicutes were obesity-associated and 7 showing it was lean-associated [18, 21, 23, 28, 29, 32, 34, 42, 43, 45, 46, 48, 50, 53–55, 59, 62, 63, 68, 69, 71];
20 studies reported significant changes in Bacteroidetes with 8 studies showing it was obesity-associated and 12 showing it was lean-associated [20, 23, 29, 31, 32, 35, 37, 43, 46, 55, 57, 59, 61 – 63, 68, 69, 71, 74, 75]. Fifteen studies reported significant change in Proteobacteria with 13 studies showing it was obesity-associated and 2 showing it was lean-associated [19, 20, 22, 29, 31, 32, 45, 46, 55, 59, 61, 65, 68, 69, 71]. Studies consistently reported that Fusobacteria as obesity-associated taxa (n = 5) [18, 20, 22, 32, 61], Actinobacteria was a lean-associated taxa (n = 7) [20, 23, 32, 45, 62, 68, 69] and Tenericutes was lean-associated (n = 4) [20, 22, 48, 77]. The details on the differential levels of taxon in each eligible study are shown in Supplementary table 1.

At lower taxonomic levels, studies consistently reported the class Bacilli, Gammaproteobacteria and family Coriobacteriaceae to be obesity-associated. Controversial results were reported for class Clostridia, family Lachnospiraceae, Rikenellaceae, and Ruminococcaceae (Supplementary table 2). At the genus level, Alistipes, Akkermansia, Bifidobacterium, Desalfovibrio, and genera in the Clostridium cluster IV (Faecalibacterium, Eubacterium, Oscillospira, Odoribacter) were the most reported lean-associated genera, while Prevotella, Lactobacillus, Blautia, Escherichia, Succinivibrio, and Fusobacterium were the most reported obesity-associated genera. Significant change in genera Ruminococcus, Coprococcus, Dialister, Bacteroides, Clostridium and Roseburia were reported but results were controversial (Table 3).

Secondary outcomes
Forty (67%) studies provided alpha diversity of the gut microbiota. Among them, 18 reported significant reduction in diversity while four reported significant increase of alpha diversity in obesity and metabolic disorders compared with controls. The remaining studies (n = 18) found no significant difference in alpha diversity between both groups. In addition, 11 studies demonstrated significant difference in β-diversity [20, 23, 27, 28, 32, 40, 47, 45, 55, 58, 66, 69], while 10 studies showed no significant difference in β-diversity between patients with obesity and metabolic disorders and controls [24, 26, 38, 49, 50, 57, 65, 70, 74, 79]. Twenty-two (37%) studies reported Firmicutes/Bacteroidetes (F/B) ratio [51 – 54, 56 – 68, 71 – 75]. Among them, eight studies reported significant increase [34 – 36, 39, 48, 52, 59, 75] and three studies reported a significant decreased in F/B ratio [33, 41, 44]. Eleven studies reported no significant change in F/B ratio in patients with obesity and metabolic disorders compared with controls (Supplementary Table 3) [37, 42, 46, 53, 54, 60 – 63, 67, 68].

Difference of microbiota between adult and childhood obesity
The trend for most microbial changes in adult and childhood obesity were consistent. Studies reported Actinobacteria as lean-associated, while Proteobacteria and Firmicutes as obesity-associated in both adults and childhood obesity. However, discrepancies were observed for several genera. Three studies in adults consistently reported that Fusobacterium was obesity-associated, but controversial results were found in children [18, 20, 22, 32, 61, 77]. Moreover, more studies reported that Dorea [39, 46, 49, 77] and Ruminococcus [39, 44, 49, 69] were obesity-associated in adults, while more studies reported them to be lean-associated in children [19, 68]. Three studies consistently reported that Turicibacter was lean-associated in adults [44, 66, 69], but one study reported it to be obesity-associated in children.

Table 2 Differentially abundant phyla in obesity/metabolic diseases

| No. of studies | 3 or more papers with obese/metabolic diseases | 2 papers with obese/metabolic diseases | 1 paper with obese/metabolic diseases | 0 paper with obese/metabolic diseases |
|----------------|-----------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| 3 or more papers with lean/metabolically healthy | Bacteroidetes (8, 12)* | – | – | Tenericutes (4) |
| 2 papers with lean/metabolically healthy | Firmicutes (7, 15) | – | – | Actinobacteria (7) |
| 1 paper with lean/metabolically healthy | Proteobacteria (13) | – | Verrucomicrobia | – |
| 0 paper with lean/metabolically healthy | Fusobacteria (5) | Acidobacteria | – | Cyanobacteria |

*n (lean/metabolically healthy, obese/metabolic diseases)
Table 3 Differentially abundant genera in obesity/metabolic diseases

| No. of studies | 3 or more papers with obesity-associated | 2 papers with obesity-associated | 1 paper with obesity-associated | 0 paper with obesity-associated |
|----------------|----------------------------------------|----------------------------------|----------------------------------|----------------------------------|
| 3 or more papers with lean-associated | Faecalibacterium (13,3) [18–20, 22, 26, 44, 46, 58, 59, 66, 69, 71, 72] | Bifidobacterium (6) [20–22, 57, 58, 68] | Alistipes (10) [20, 26, 44, 53, 58–60, 68, 76, 77] | Odoribacter (6) [29, 44, 59, 60, 77, 78] |
| | Prevotella (5,8) [26, 38, 67, 72, 73, 75] | Roseburia (4) [53, 63, 66, 68, 69, 79] | Akkermansia (9) [23, 28, 36, 44, 45, 47, 49, 65, 70] | Oscillibacter (6) [20, 36, 68, 70, 75, 77] |
| | Bacteroides (6,4) [18, 24, 26, 41, 43, 44, 46, 48, 69, 72] | Clostridium (4) [20, 38, 46, 49, 53, 72] | Tunicibacter (3) | Oscillibacter (4) |
| | Ruminococcus (4, 5) [20, 23, 39, 44, 49, 62, 63, 68, 69] | | | |
| | Dialister (4,4) [19, 20, 36, 50, 55, 70, 72, 79] | | | |
| | Lactobacillus (3,6) [19, 21, 38, 46, 57, 60] | | | |
| | Coprococcus (3, 5) [18, 23, 44, 48, 63, 68, 69, 71] | | | |
| | Blautia (3,6) [38, 39, 44, 48, 73, 74] | | | |
| 2 papers with lean-associated | Streptococcus (4) | Bilophila | Holdemania | Oxalobacter |
| | Lachnospira (3) | | | Methanoregulibacter |
| | Fusobacterium (4) [18, 20, 22, 44] | | | Acholeplasma |
| | | | gemmiger | |
| 1 paper with lean-associated | Phascolarctobacte (3) | Sutterella | Veillonella | Haemophilus |
| | Dorea (4) | Megasphaera | Staphylococcus | Anaerostipes |
| | Collinsella (3) | Megamonas | Rothia | Paraeribacteroides |
| | Acidaminococcus (3) | Adlercreutzia | Pseudomonas | |
| 0 paper with lean-associated | Succinivibrio (3) [38, 69, 78] | SM83 | Alloprevotella | |
| | Escherichia (3) [57, 60, 68] | Porphyromonas | Lachnospiraceae incertae sedis | |
| | | Peptoniphilus | Burkholderiales | |
| | | Mitsuokella | | |
| | | Escherichia-Shiguela | | |
| | | Catenibacterium | | |
| | | Bacillus | | |
| | | Aggregatibacter | | |

* n (lean-associated, obesity-associated)

For most studies used 16s rRNA sequencing, which lacks species resolution, Faecalibacterium prausnitzii, and Akkermansia muciniphila were combined with respective genera as they were the primary species that constitute respective genera.

[20]. Notably, three studies in adults reported that the genus *Bifidobacterium* was lean-associated [22, 57, 58], while controversial results were found in children (3 lean-associated and 2 obesity-associated) [19–21, 38, 68]. These findings suggested that microbiota in childhood obesity and metabolic disorders were more heterogeneous compared with adults.

**Difference of microbiota between the East and the West**

Large discrepancies in gut microbiome in obesity and metabolic disorders were observed in studies from the East and the West. Four studies exclusively consisting of populations in the West reported that the Family Coriobacteriaceae was obesity-associated [27, 38, 53, 71] whereas none in the East reported significant change of this bacterial family between obese subjects and controls. Four studies in the East reported that the family Ruminococcaceae was lean-associated [22, 60, 61, 63], but conflicting results were found in studies from the West (2 lean-associated and 2 obesity-associated) [27, 36, 43, 68]. At the genus level, four studies reported that *Prevote
tella* was lean-associated in the East (3 lean-associated
and 1 obesity-associated) [19, 20, 26, 61], while other studies from the West have reported it to be obesity-associated (2 lean-associated and 5 obesity-associated) [38, 55, 67, 68, 72, 73, 75]. Three studies reported that Ruminococcus was lean-associated in the East [20, 63, 67], but most studies reported it to be obesity-associated in the West (1 lean-associated and 5 obesity-associated) [23, 39, 44, 49, 62, 69]. Similar findings were observed for Roseburia (3 lean-associated in the east [30, 63, 66], 1 lean-associated and 2 obesity-associated in the west [53, 68, 69]). Notably, the common genus Lactobacillus was repeatedly reported to be obesity-associated in the West (1 lean-associated and 4 obesity-associated) [19, 38, 44, 46, 57]. Controversial results for Lactobacillus were also reported in the East (2 lean-associated and 2 obesity-associated) [21, 59, 60, 63].

Quality of the evidence

The Newcastle Ottawa Scale showed that all 60 studies provided an adequate explanation in the definition and selection method for patients with obesity and metabolic disorders (Table 4). Fifty-five (91.7%) of 60 studies did the same process for controls. Twenty (33.3%) and 27 (45%) studies demonstrated comparable data of sex and age in patients with obesity / metabolic disorders and controls.

Discussion

To our knowledge, this is the most comprehensive systematic review in microbiota and obesity and metabolic disorders, as we extracted the data of each available bacterial group using the lowest taxonomic level based on NGS of each included study. We believe that the findings reflect the best available current evidence demonstrating the relationship between individual bacterial taxa and obesity or metabolic disorders.

Proteobacteria was the most consistently reported obesity-associated phylum. Several members of Proteobacteria, such as Proteus mirabilis and E. coli, were potential drivers of inflammation in the gastrointestinal tract [7, 80, 81]. Low-grade inflammation is a risk factor for developing metabolic diseases including atherosclerosis, insulin resistance, and diabetes mellitus [82]. Besides stool microbiota, obese subjects with T2DM also showed a high bacterial load with an increase in Enterobacteriaceae in plasma, liver, and omental adipose tissue microbiota [83].

Lactobacillus was reported to be an obesity-associated taxon and abundance was higher in the stool of patients with obesity and metabolic diseases. This food-derived probiotic genus showed relative low prevalence and abundance in the commensal gut microbiota [52]. Previous clinical trials of Lactobacillus, alone or in combination with Bifidobacterium, showed variable efficacy in weight loss in patients with obesity [9]. These inconsistent results indicated that the underlying mechanisms of Lactobacillus (at least some of its species) in the treatment of metabolic disorders warrant further investigation. Other commensal bacteria such as Bifidobacterium spp., Alistipes spp., and Akkermansia that constitute a large proportion of the gut microbiota were frequently observed to be higher in healthy individuals than obese, metabolically affected subjects. These species might therefore exert a more durable beneficial effect for the consideration in managing obesity compared with Lactobacillus.

Akkermansia muciniphila (Actinobacteria phylum), a species identified by NGS, was one of the most commonly reported lean-associated bacteria in obesity and metabolic diseases. A. muciniphila was reported to help modulate the gut lining which could promote gut barrier function and prevent inflammation caused by the “leaky” gut [84]. A clinical trial demonstrated that supplementation with A. muciniphila could reduce body weight and decrease the level of blood markers for liver dysfunction and inflammation in obese insulin-resistant volunteers [10]. Another proof-of-concept study showed that supplementation with five strains including A. muciniphila was safe and associated with improved postprandial glucose control [85]. These findings highlight the potential of specific live biotherapeutics in weight control in subjects with obesity and metabolic diseases.

Other genera that were consistently reported to be more abundant in lean healthy individuals than obese subjects were Alistipes (Bacteroidetes phylum) and Faecalibacterium (Firmicutes phylum). Alistipes could produce small amounts of short-chain fatty acids (SCFA, acetic, isobutyric, isovaleric, and propionic acid) [86] while Faecalibacterium is one of the major butyrate producers in the human gut [87, 88]. SCFA have anti-inflammatory properties [89] and may promote weight loss through the release of glucagon-like peptide 1 that promotes satiety and the activation of brown adipose tissue via the gut–brain neural circuit [90, 91]. Butyrate could activate the GPR43-AKT-GSK3 signaling pathway to increase glucose metabolism by liver cells and improve glucose control in diabetes mice [92]. They could also inhibit the expression of PPARγ, increase fat oxidation in skeletal muscle mitochondria, and reduce lipogenesis in high-fat diet (HFD) mouse model [93].

We have identified several genera, including Bifidobacterium, Roseburia, Prevotella, and Ruminococcus, that were consistently reported to be lean-associated exclusively in subjects from the East. Bifidobacterium spp. are widely used probiotics proven to be safe and well-tolerated and exhibited a significant effect in lowering serum total cholesterol both in mice and in humans [94]. Roseburia is another major butyrate-producing...
| First author, year | Selection | Representativeness of the cases | Selection of controls | Definition of controls | Comparability | Comparability of baseline characteristic 1 (sex) | Comparability of baseline characteristic 2 (Age) | Exposure | Ascertainment of exposure | Same method of ascertainment for cases and controls | Nonresponse rate |
|-------------------|-----------|--------------------------------|-----------------------|------------------------|--------------|---------------------------------|---------------------------------|----------|-----------------------|-------------------------------|----------------|
| Andoh, 2016 [18]  | *         | *                              | *                     | *                      | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Bai, 2019 [19]    | *         | *                              | NA                    | NA                     | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Chen, 2020 [20]   | *         | *                              | *                     | *                      | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Da Silva, 2020    | *         | *                              | *                     | *                      | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Gao, 2018 [22]    | *         | *                              | *                     | *                      | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Gao, 2018 [23]    | *         | *                              | *                     | *                      | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Haro, 2016 [24]   | *         | *                              | *                     | *                      | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Hou, 2018 [25]    | *         | *                              | *                     | *                      | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Hu, 2015 [26]     | *         | *                              | *                     | *                      | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Kaplan, 2019 [27] | *         | *                              | NA                    | NA                     | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Liu, 2017 [28]    | *         | *                              | *                     | *                      | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Lopez-Contreras, 2018 [29] | *   | *                              | *                     | *                      | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Lv, 2019 [30]     | *         | *                              | NA                    | NA                     | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Mendoza-Salazar, 2018 [31] | *   | *                              | NA                    | NA                     | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Nardelli, 2020    | *         | *                              | *                     | *                      | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Blasco, 2017 [33] | *         | *                              | *                     | *                      | NA           | *                               | NA                              | NA       | NA                    | NA                            | *              |
| Davis, 2017 [34]  | *         | *                              | NA                    | NA                     | NA           | *                               | NA                              | NA       | NA                    | NA                            | *              |
| Dominianni, 2015  | *         | *                              | *                     | *                      | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Escobar, 2015 [36] | *         | *                              | *                     | *                      | NA           | *                               | NA                              | NA       | NA                    | NA                            | *              |
| Kasai, 2015 [37]  | *         | *                              | *                     | *                      | *            | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Nirmalkar, 2018 [38] | *     | *                              | *                     | *                      | NA           | *                               | NA                              | NA       | NA                    | NA                            | *              |
| Ottosson, 2018    | *         | *                              | *                     | *                      | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
| Peters, 2018 [40] | *         | *                              | *                     | *                      | NA           | *                               | NA                              | NA       | NA                    | NA                            | *              |
| Ppartil, 2012 [41] | *         | *                              | *                     | *                      | NA           | NA                              | NA                              | NA       | NA                    | NA                            | *              |
### Table 4: Quality of each included study by the Newcastle Ottawa Scale (Continued)

| Study                              | Selection | Comparability | Exposure | Outcome | Overall |
|------------------------------------|-----------|---------------|----------|---------|---------|
| Rahat-Rozenblom, 2014 [42]         | *         | *             | *        | *       | *       |
| Riva, 2017 [43]                    | *         | *             | *        | *       | *       |
| Vieira-Silva, 2020 [44]            | *         | *             | NA       | NA      | NA      |
| Ville, 2020 [45]                   | *         | *             | *        | NA      | NA      |
| Yasir, 2015 [46]                   | *         | *             | *        | NA      | NA      |
| Yun, 2017 [47]                     | *         | *             | *        | NA      | NA      |
| Zacarias, 2018 [48]                | *         | *             | NA       | *       | NA      |
| Allin, 2018 [49]                   | *         | *             | *        | *       | *       |
| Barengolts, 2018 [50]              | *         | *             | NA       | *       | NA      |
| Leite, 2017 [51]                   | *         | *             | *        | NA      | NA      |
| Qin, 2012 [52]                     | *         | *             | *        | NA      | NA      |
| Karlsson, 2013 [53]                | *         | *             | NA       | NA      | NA      |
| Larsen, 2010 [54]                  | *         | *             | *        | NA      | NA      |
| Ahmad, 2019 [55]                   | *         | *             | *        | NA      | NA      |
| Koo, 2019 [56]                     | *         | *             | *        | *       | *       |
| Sroka-oleksjak, 2020 [57]          | *         | *             | NA       | *       | NA      |
| Thingholm, 2019 [58]               | *         | *             | *        | NA      | NA      |
| Zhao, 2019 [59]                    | *         | *             | *        | NA      | NA      |
| Jiang, 2018 [60]                   | *         | *             | *        | *       | *       |
| Shen, 2017 [61]                    | *         | *             | *        | NA      | NA      |
| Sobhonslidsuk, 2018 [62]           | *         | *             | *        | NA      | NA      |
| Wang, 2016 [63]                    | *         | *             | NA       | NA      | NA      |
| Li, 2018 [64]                      | *         | *             | *        | NA      | NA      |
| Nistal, 2019 [65]                  | *         | *             | *        | NA      | NA      |
| Yun, 2019 [66]                     | *         | *             | *        | NA      | NA      |
| Michail, 2015 [67]                 | *         | *             | NA       | NA      | NA      |
Table 4 Quality of each included study by the Newcastle Ottawa Scale (Continued)

| Study                        | #1 | #2 | #3 | #4 | #5 | #6 | #7 | #8 | #9 | #10 | #11 |
|------------------------------|----|----|----|----|----|----|----|----|----|-----|-----|
| Zhu, 2013 [68]               | *  |    | *  |    | NA |    | NA | NA | NA | NA  | *   |
| Chavez-Carbajal, 2019 [69]  | *  |    | *  |    | NA |    | *  | NA | NA | NA  | *   |
| De La Guesta-Zuluaga, 2018 [70] | * | *  | NA |    | NA |    | *  | NA | NA | NA  | *   |
| Gallardo-Becerra, 2020 [71]  | *  | NA | NA | NA | NA |    | *  | NA | NA | NA  | *   |
| Gozd-Barszczewska, 2017 [72] | *  |    | NA | NA | NA | NA |    | NA | NA | NA  | *   |
| Kashtanova, 2018 [73]        | *  | *  | NA | NA | NA |    | NA | NA | NA | NA  | *   |
| Lippert, 2017 [74]           | *  | *  | *  | NA |    | NA | NA | NA | NA | NA  | *   |
| Feinn, 2020 [75]             | *  | *  | *  | NA |    | NA | NA | NA | NA | NA  | *   |
| Li, 2021 [76]                | *  | *  | *  | *  |    | NA | NA | NA | NA | NA  | *   |
| Yuan, 2021 [77]              | *  | *  | *  | NA |    | NA | NA | NA | NA | NA  | *   |

* NA not applicable
genus of the human gut [95]. R. intestinalis could maintain the gut barrier function through upregulation of the tight junction protein [96]. Supplementation of R. intestinalis and R. hominis could ameliorate alcoholic fatty liver disease in mice [97]. Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon [98]. Prevotella copri (Bacteroidetes phylum) was found to improve aberrant glucose tolerance syndromes and enhance hepatic glycogen storage in animals via the production of succinate [99]. However, a recent study also showed that the prevalence of P. copri exacerbated glucose tolerance and enhanced insulin resistance which occur before the development of ischemic cardiovascular disease and type 2 diabetes [100].

Only limited human studies in the current review reported an increased ratio of F/B in obesity. An increased ratio of F/B was shown in studies of the high-fat diet mouse model [6]. No taxon distinction was found to be specific for any type of metabolic disease. This was in line with a recent study that showed obesity, but not type 2 diabetes, was associated with notable alterations in microbiome composition [58].

The strength of this study is that we applied a robust method of grouping various types of disease-microbiome associations into “lean, metabolically healthy state” or “obese, metabolically diseased state.” Despite various metabolic disorders may affect the gut microbiota in different manners, the inter-study variation often supersedes the intra-study variation between disease and control groups [101]. Overall, the most striking observation is the lack of consistency in results between studies. This probably relates to the limitations of the studies included in this review. Also, it relies on the striking stability and individuality of adult microbiota, changing over time. Heterogeneity between studies is often a problem in systematic reviews. Several different methods were used to assess the microbiota, which makes it difficult to compare results between studies and likely contributes to the differences in results. While the standardization of study protocol (sample storage, DNA extraction, sequencing, analysis methods, and stringent subject recruitment criteria) could potentially result in comparable data between studies, this remains a big challenge across different regions. Moreover, we excluded studies that used species- or group-specific primers for microbiota assessment because such methods could only capture certain bacterial groups. This limits the total number of studies included. For robust microbiota results that are comparable among studies, there need to be efforts for standardization of sample storage, DNA extraction, sequencing, and analysis methods among groups undertaking gut microbiota studies. Finally, longitudinal studies would allow for a more robust association of changes in the microbiota to changes in obesity and metabolic disorders.

**Conclusions**

This systematic review identified consistent evidence for several lean-associated genera that may have therapeutic potential for obesity and metabolic diseases. Besides A. muciniphila, species from genera Faecalibacterium, Alitipes, and Roseburia might also harbor therapeutic potentials against obesity and metabolic diseases. These results provided a guide for the future development of certain bacteria into live biotherapeutics that may be helpful for the management of obesity and metabolic disorders. Further in-vitro and in-vivo research are needed to elucidate their role in the management of obesity and metabolic diseases.

**Appendix. Searching strategy**

1. obese.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
2. obesity.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
3. overweight.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
4. microbiota.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
5. microbiome.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
6. fecal.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
7. faecal.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
8. gut.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
9. intestinal.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
10. 1 or 2 or 3
11. 4 or 5
12. 6 or 7 or 8 or 9
13. 10 and 11 and 12
14. metagenomics.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
15. metagenomic.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
16. 16s.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
17. 14 or 15 or 16
18. 13 and 17
19. remove duplicates from 18
20. metabolic disease.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
21. 10 or 20
22. 11 and 12 and 21
23. 17 and 22
24 remove duplicates from 23
25 limit 24 to full text

Abbreviations
OB: Obesity; T2DM: Type 2 diabetes; NAFLD: Non-alcoholic fatty liver disease; NGS: Next-generation sequencing; BMI: Body mass index; F/B: Firmicutes/ Bacteroidetes; NASH: Non-alcoholic steatohepatitis; OMS: Obese with metabolic syndrome; SCFA: Short-chain fatty acids; HFD: High-fat diet

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12263-021-00703-6.

Additional file 1. Supplementary Table 1: Differentially abundant taxa at each taxonomic level in patients with obesity and metabolic diseases reported in individual studies. Supplementary Table 2. Differentially abundant taxa at class, order, and family level in obesity / metabolic diseases. Supplementary Table 3. Microbiota diversity and F/B Ratio in Obesity / metabolic diseases.

Acknowledgements
Not applicable.

Authors’ contributions
All authors contributed to the analysis and interpretation of data, the writing and critical revision of manuscript at all stages of development. All authors read and approved the final manuscript.

Funding
It was funded by InnoHK, The Government of Hong Kong, Special Administrative Region of the People’s Republic of China.

Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
Francis Chan and Siew Ng are co-founders and in the board of GenieBiome Ltd. Siew Ng has served as an advisory board member for Pfizer, Ferring, Janssen, and Abbvie and a speaker for Ferring, Tillotts, Menarini, Janssen, Abbvie, and Takeda. She has received research grants from Olympus, Ferring, and Abbvie. Francis Chan has served as an advisor and lecturer speaker for Eisai Co., Ltd., AstraZeneca, Pfizer Inc., Takeda Pharmaceutical Co., and Takeda (China) Holdings Co. Ltd. XU Zhilu is an employee of GenieBiome Ltd. All other authors declare that there are no competing interests.

Author details
1Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Diseases, LKS Institute of Health Science, The Chinese University of Hong Kong, Hong Kong, China. 2Center for Gut microbiota research, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. 3Microbiota Innovation Centre (MagIC Centre), The Chinese University of Hong Kong, Hong Kong, China.

Received: 23 August 2021 Accepted: 23 November 2021

Published online: 29 January 2022

References
1. Banack HR, Kaufman JS. The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. Prev Med. 2014;62:96–102. https://doi.org/10.1016/j.ypmed.2014.02.003.
2. WHO. Obesity and overweight, World Health Organization. 2017. http://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 12 Jan 2018.
3. Turnbaugh PJ, Ley RE, Mahowald MA, Maginini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31. https://doi.org/10.1038/na05414.
4. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480–4. https://doi.org/10.1038/nature07540.
5. Castaner O, Goday A, Park YM, Lee SH, Magkos F, Shiyou SATE, et al. The gut microbiome profile in obesity: a systematic review. Int J Endocrinol. 2018;2018:4965789. https://doi.org/10.1155/2018/4965789.
6. Bisanz JE, Udupathy V, Turnbaugh JA, Ly K, Turnbaugh PJ. Meta-analysis reveals reproducible gut microbiome alterations in response to a high-fat diet. Cell Host Microbe. 2019;26(2):265–72.e4.
7. Allegr etti RR, Kassam Z, Mullish BH, Chiang A, Carrellas M, Hurtado J, et al. Effects of Fecal Microbiota transplantation with oral capsules in obese patients. Clin Gastroenterol Hepatol. 2020;18(4):655–63.e2. https://doi.org/10.1016/j.cgh.2019.07.006.
8. Yu EW, Gao L, Stastka P, Cheney MC, Mahabannungu JE, Torres Soto M, et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: the FMT-TRIM double-blind placebo-controlled pilot trial. PLoS Med. 2020;17(3):e1003051. https://doi.org/10.1371/journal.pmed.1003051.
9. Borgeraas H, Johnson LK, Skattebu J, Hjelmesaeth J. Effects of probiotics on body weight, body mass index, fat mass and fat percentage in subjects with overweight or obesity: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2018;19(2):219–32. https://doi.org/10.1111/obr.12626.
10. Depommier C, Everard A, Druart C, Plocher H, van Hul M, Vieira-Silva S, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096–103. https://doi.org/10.1038/s41591-019-0496-2.
11. Nam YD, Jung MJ, Roh SW, Kim MS, Bae JW. Comparative analysis of Korean human gut microbiota by barcoded pyrosequencing. PLoS One. 2011;6(7):e22109. https://doi.org/10.1371/journal.pone.0022109.
12. Deschaisaux M, Bouter KE, Prodan A, et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. Nat Med. 2018;24(10):1526.
13. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222.
14. Hayashi H, Sakamoto M, Benno Y. Fecal microbial diversity in a strict vegetarian as determined by molecular analysis and cultivation. Microbiol Immunol. 2002;46(12):819–31. https://doi.org/10.1111/j.1348-0421.2002.tb02766x.
15. Mueller S, Saunier K, Hanisch C, Norir E, Alm L, Midveldt T, et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol. 2006;72(2):1027–33. https://doi.org/10.1128/AEM.72.1.1027-1.2006.
16. Hollister EB, Riehe K, Luna RA, Weider EM, Rubio-Gonzales M, Mistretta TA, et al. Structure and function of the healthy pre-adolescent pediatric gut microbiome. Microbiome. 2015;3(1):36. https://doi.org/10.1186/s40168-015-0101-x.
17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Bmj. 2009;339(7326):52–60. https://doi.org/10.1136/bmj.39602.74073.ad.
18. Andoh A, Nishida K, Inatomi O, Imaeda H, Bamba S, et al. Comparison of the gut microbiota profile in obesity: a systematic review. Int J Endocrinol. 2018;2018:457(7228):480–4. https://doi.org/10.1038/nature07540.
19. Bai J, Hu Y, Bruner DW. Composition of gut microbiota and its association with body mass index and lifestyle factors in a cohort of 7-18 years old children from the American Gut Project. Pediatr Obes. 2019;14(4):e12480. https://doi.org/10.1111/pob.12480.
20. Chen X, Sun H, Jiang F, Shen Y, Li X, Hu X, et al. Alteration of the gut microbiota associated with childhood obesity by 16S rRNA gene sequencing. PeerJ. 2020;2020(1):e8317. https://doi.org/10.7717/peerj.8317.
21. Da Silva CC, Montell MA, Davis EM. Overweight and obesity in children are associated with an abundance of Firmicutes and Reduction of Bifidobacterium in their gastrointestinal microbiota. Child Obes (Print). 2020;16(3):204–10. https://doi.org/10.1089/chi.2019.0280.
22. Gao R, Zhu C, Li H, Yin M, Pan C, Huang L, et al. Dysbiosis signatures of gut microbiota along the sequence from healthy, young patients to those with...
overweight and obesity. Obesity. 2018;26(2):351–61. https://doi.org/10.1002/oby.22088.

23. Gao X, Jia R, Xie X, Luan K, Feng L, Wan C. A study of the correlation between obesity and intestinal flora in school-age children. Sci Rep. 2018; 8(1):14511. https://doi.org/10.1038/s41598-018-32730-6.

24. Haro C, Ringel-Zuniga OA, Alcala-Diaz JF, et al. Intestinal microbiota is influenced by gender and body mass index. PLoS One. 2016;11(5):e0154090. https://doi.org/10.1371/journal.pone.0154090.

25. Houttu N, Mokkala K, Laitinen K. Overweight and obesity status in pregnant women are related to intestinal microbiota and serum metabolic and inflammatory profiles. Clin Nutr. 2018;37(6):1955–66. https://doi.org/10.1016/j.clnu.2017.12.013.

26. Hu H-J, Park S-G, Jang HB, Choi MG, Park KH, Kang IH, et al. Obesity alters the microbial community profile in Korean adolescents. PLoS One. 2015; 10(7):e0134333. https://doi.org/10.1371/journal.pone.0134333.

27. Kaplan RC, Wang Z, Usyk M, Sotres-Alvarez D, Davigliui ML, Schneiderman N, et al. Gut microbiome composition in the comparison of American adults. Sci Rep. 2015; 57(1):1219. https://doi.org/10.1186/s13059-015-1831-z.

28. Liu R, Hong J, Feng Q, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med. 2017; 23(7):859–68. https://doi.org/10.1038/nm.4358.

29. Lopez-Contreras BE, Moran-Ramos S, Villarreal-Vazquez R, et al. Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits. Pediatr Obes. 2018;13(6):381–8. https://doi.org/10.1111/ijpo.12262.

30. Lv Y, Qin X, Jia H, Chen S, Sun W, Wang X. The association between gut microbiota composition and BMI in Chinese male college students, as assessed using effect size statistic. MicrobiologyOpen. 2017;6(4):e00476. https://doi.org/10.1002/mbo3.476.

31. Mendez-Salazar EO, Granados-Silvestre MDLA, Palacios-Huerta E, et al. Intestinal microbiota is associated with inflammation and impaired mucosal immune function in type 1 diabetes. J Clin Endocrinol Metab. 2018;103(4):1491–500. https://doi.org/10.1210/jc.2017-02114.

32. Nirmalkar K, Murugesan S, Pizano-Zarate ML, et al. Gut microbiota and endodontal dysfunction markers in obese Mexican children and adolescents. Nutrients. 2018;10(12):2009. https://doi.org/10.3390/nu10122009.

33. Ottosson F, Brunnwall L, Ericson U, Nilsson PM, Almgren P, Fernandez C, et al. Connection between BMI-related plasma metabolite profile and gut microbiota. J Clin Endocrinol Metab. 2018;103(4):1491–501. https://doi.org/10.1210/jc.2017-02114.

34. Peters BA, Shapiro LA, Church TR, Miller G, Trinh-Shевrin C, Yuen E, et al. A taxonomic signature of obesity in a large study of American adults. Sci Rep. 2018;8(1):19749. https://doi.org/10.1038/s41598-018-28126-1.

35. Ppatil D, Pdhrote D, Gchavan S, et al. Molecular analysis of gut microbiota in obesity among Indian individuals. J Biosci. 2012;37(4):647–57. https://doi.org/10.1007/s12038-012-9244-0.
63. Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep. 2016;6(1):32002. https://doi.org/10.1038/srep32002.

64. Li F, Sun G, Wang Z, Wu W, Gao H, Peng L, et al. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients. Sci China Life Sci. 2018;61(7):717-720. https://doi.org/10.1007/s11427-017-9303-9.

65. Nistal E, Saenz de Miera LE, Ballesteros PM, et al. An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity. Rev Esp Enferm Dig. 2019;111(4):275-282. https://doi.org/10.1016/j.redgastro.2018.06.068.

66. Yun Y, Kim HN, Lee EJ, Ryu S, Chang Y, Shin H, et al. Fecal and blood microbiota profiles and presence of non-alcoholic fatty liver disease in obese versus lean subjects. PLoS One. 2019;14(3):e0213692. https://doi.org/10.1371/journal.pone.0213692.

67. Michal S, Lin M, Frey MR, Fanter R, Palli O, Hiltibush B, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015;91(2):1-9. https://doi.org/10.1093/femsec/fiu002.

68. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601-607. https://doi.org/10.1002/hep.26093.

69. Casabé J, Alarcon S, Garcia-Granados F, Garcia-Lopez R, et al. Characterization of the gut microbiota of patients with non-alcoholic fatty liver disease (NAFLD). Sci China Life Sci. 2018;61(7):717-720. https://doi.org/10.1007/s11427-017-9303-9.

70. Casabé J, Alarcon S, Garcia-Granados F, Garcia-Lopez R, et al. Characterization of the gut microbiota of patients with non-alcoholic fatty liver disease (NAFLD). Sci China Life Sci. 2018;61(7):717-720. https://doi.org/10.1007/s11427-017-9303-9.

71. Elasoux C, Alcaraz P, Vidal J, et al. Alteration of gut microbiota composition in obese and non-obese patients with NAFLD. J Hepatol. 2019;71(2):390-397. https://doi.org/10.1016/j.jhep.2019.01.007.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.